One such investigation is that by Stuelten et al who evaluated the expression patterns of seven markers generally associated with stemness (CD15, CD24, CD44, CD133, CD166, CD326, PgP) in the NCI60 tumor cell line panel that comprises lung, colon, breast, skin cancer as well as hematopoietic malignancies, and brain cancer.34 That study, however, did not focus on stemness markers specific for glioblastoma but rather used a generic stemness marker panel. This evidence concerns the gene PROM1 and neoplasm.